ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Lilly boosts immuno-oncology pipeline with $1.6B Armo buy
fiercebiotech
May 16, 2018Eli Lilly is ponying up about $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin, which has shown promise both as a single agent and in combination treatments for multiple tumor types.
Pharma Sources Insight January 2025
